02:22:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-08-09 Halvårsrapport
2024-06-13 Årsstämma
2024-05-02 X-dag ordinarie utdelning BONEH 0.00 EUR
2024-02-26 Bokslutskommuniké 2023
2023-10-23 Extra Bolagsstämma 2023
2023-08-25 Halvårsrapport
2023-05-02 X-dag ordinarie utdelning BONEH 0.00 EUR
2023-04-28 Årsstämma
2023-02-24 Bokslutskommuniké 2022
2022-08-25 Halvårsrapport
2022-04-29 X-dag ordinarie utdelning BONEH 0.00 EUR
2022-04-28 Årsstämma
2022-03-17 Extra Bolagsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-08-25 Halvårsrapport
2021-04-29 X-dag ordinarie utdelning BONEH 0.00 EUR
2021-04-28 Årsstämma
2021-02-24 Bokslutskommuniké 2020
2020-08-31 Halvårsrapport
2020-04-06 X-dag ordinarie utdelning BONEH 0.00 EUR
2020-04-05 Årsstämma
2020-03-20 Bokslutskommuniké 2019
2019-08-30 Halvårsrapport
2019-04-08 X-dag ordinarie utdelning BONEH 0.00 EUR
2019-04-05 Årsstämma
2018-08-30 Halvårsrapport
2018-03-29 Årsstämma

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
2022-12-22 14:45:00

BBS-Bioactive Bone Substitutes Plc, Investor News, 22 December 2022 at 3.45 p.m.

The management team of BBS-Bioactive Bone Substitutes Plc (BBS), including CEO Ilkka Kangasniemi, Chairman of the Board Jarmo Halonen, and Board Member Pekka Jalovaara, met with Minister of Economic Affairs Mika Lintilä and MP Mikko Kinnunen on Wednesday (21 December 2022) at the Finnish Parliament Building in Helsinki.

During the meeting, they discussed the future prospects of the company and the potential benefits of its solutions, both for patients and for Finland as a whole.

BBS, founded in 2003, has developed ARTEBONE® Paste, a next-generation treatment for severe bone fractures and ossification issues. The company is currently seeking CE marking for the product, which would allow for commercialization in the European Union.

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares are listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi